SeXX Matters for Respiratory Viral Pathogenesis and Responses to Vaccines

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor, Department of Molecular Microbiology & Immunology, Biochemistry & Molecular Biology and International Health John Hopkins Bloomberg School of Public Health Co-director...
    BIOGRAPHY

Abstract

The ongoing COVID-19 pandemic has increased awareness about sex-specific differences in immunity and outcomes following respiratory virus infections. Strong evidence of a male bias in COVID-19 disease severity will be presented based on clinical data and preclinical animals models, which illustrate sex differential immune responses against SARS-CoV-2. Prior to the pandemic, data from other viral infections, including influenza viruses, showed profound sex differences in virus-specific immunity, including locally in the respiratory tract. We  have used influenza A viruses to interrogate sex-specific immunity to infection and vaccination. Although males are more susceptible to most viral infections, females possess immunological features that contribute to greater vulnerability to immune-mediated pathology but also better protection following vaccination. Both sex chromosome complement and related X-linked genes (e.g., TLR7) as well as sex steroids, including estrogens and androgens, play important roles in mediating the development of sex differences in immunity to respiratory viral infections and vaccination.

Learning objectives:

1.    Definition of biological sex and distinction from gender, with consideration of diverse respiratory viruses.

2.    Characterization of sex differences in respiratory virus pathogenesis in humans and animal models, with emphasis on influenza A viruses and SARS-CoV-2.

3.    Insights into the genetic and hormonal mechanisms that underlie sex differences in immunity to respiratory virus infection and vaccination.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
FEB 24, 2022 10:00 AM PST
C.E. CREDITS
FEB 24, 2022 10:00 AM PST
Date: February 24, 2021 Time: 10:00am (PST), 1:00pm (EST) One of the largest global public health crises is the rise of antimicrobial-resistant infections. Globally, over 700,000 people die...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
JAN 13, 2022 9:00 AM PST
C.E. CREDITS
JAN 13, 2022 9:00 AM PST
Date: January 13, 2022 Time: 09:00am (PST), 12:00pm (EST) Recently, the Infectious Disease Society of America released guidance on how to approach treatment of infections caused by multidrug...
Loading Comments...
Show Resources